Share Early results of an active Phase II clinical trial show promise in maintaining or improving vision in wet AMD.  The treatment, developed by Regeneron and called VEGF-Trap-Eye, is an injection into the eye.

Share One of the most exciting avenues of research for macular degeneration involves the use of the stem cells to treat vision loss.  Researchers at the University of California, Irvine, have made important progress towards this goal. In the online Journal of Neuroscience Methods, they report that they have created an eight-layer, early stage retina from human embryonic stem cells. 

Share A comprehensive dilated eye exam is a painless procedure in which an eye care professional examines your eyes to look for common vision problems and eye diseases, many of which have no early warning signs. Regular comprehensive eye exams can help you protect your sight and make sure that you are seeing your best.

By:  Bill Takeshita, OD

Share Prescription filters are one of the most important visual aids that people with macular degeneration will benefit from wearing.  The ultra-violet radiation and blue wavelengths of light can potentially damage the cells of the retina and too much light can actually reduce a person's ability to see, especially under very bright sunlight. 

Share This issue is a particularly sensitive one for seniors who also have macular degeneration or other conditions that impair their vision. Driving means independence and most people want to hold on to their cars as long as possible. When is it time to stop?

Share The National Eye Institute just released this information about an ongoing study of gene therapy for Leber congenital amaurosis, a retinal disease affecting younger people.  Although this research was conducted with people who did not have age-related macular degeneration, the results are encouraging for similar therapies for AMD.  All three subjects had maintained their previous visual gains.  

Share MacuSight is currently recruiting patients with wet AMD for a Phase 2 study of an ocular sirolimus formulation in combination with Lucentis®.  This is a randomized, multi-center study and is taking place throughout the United States.